Laddar...
PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer
In recent years, the deoxycytidine analogue gemcitabine (2′,2′,-difluorodeoxycytidine) has become the first-line chemotherapeutic agent for patients with pancreatic cancer. However, due to the intrinsic resistance of pancreatic cancer cells, gemcitabine-based chemotherapy yields limited disease cont...
Sparad:
| I publikationen: | Exp Mol Med |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Nature Publishing Group UK
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7156657/ https://ncbi.nlm.nih.gov/pubmed/32123287 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s12276-020-0390-4 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|